This inventor holds 1 USPTO granted patent and 2 published patent applications and 2 EPO patents. Top assignees: Foundation for Biomedical Research and Innovation, Keio University, Morishita Jintan Co., Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2025
Title: Takuhiko Adachi: Innovator in Ulcerative Colitis Treatment
Introduction
Takuhiko Adachi is a notable inventor based in Hirakata, Japan. He has made significant contributions to the field of medicine, particularly in the treatment of ulcerative colitis. His innovative approach has led to the development of a unique capsule designed to enhance the effectiveness of treatment while minimizing side effects.
Latest Patents
One of Takuhiko Adachi's key inventions is a capsule for treating ulcerative colitis. This capsule is designed to disintegrate locally in the large intestine, which allows for more effective treatment compared to conventional methods. The capsule contains indigo, a drug known for its therapeutic properties against ulcerative colitis. The innovative design includes a protective layer and a film that ensures the capsule does not disintegrate until it reaches the large intestine, thereby reducing the risk of hepatotoxicity.
Career Highlights
Throughout his career, Takuhiko Adachi has worked with prestigious institutions such as Keio University and the Foundation for Biomedical Research and Innovation at Kobe. His work has been instrumental in advancing medical treatments and improving patient outcomes.
Collaborations
Takuhiko Adachi has collaborated with notable colleagues, including Takanori Kanai and Hideo Nishimura. These partnerships have contributed to the development and refinement of his innovative medical solutions.
Conclusion
Takuhiko Adachi's contributions to the treatment of ulcerative colitis through his patented capsule demonstrate his commitment to medical innovation. His work continues to impact the field positively, offering hope for improved treatment options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile